Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00240331
Status:
COMPLETED
Last Update Posted:
2011-05-19
First Post:
2005-10-16
Brief Title:
AURORA Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease ESRD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis an Assessment of Survival and Cardiovascular Events AURORA A Double Blind Randomised Phase 3b Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival Cardiovascular Events When Given to Subjects With End-stage Renal Failure on Chronic Haemodialysis Treatment
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks strokes and cardiovascular deaths in patients undergoing haemodialysis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| D3562C00096 | None | None | None |